OR WAIT null SECS
September 20, 2019
Novo Nordisk has revealed the findings from an exploratory analysis of Phase IIIa clinical development program, demonstrating improved glycemic control with oral semaglutide.
Procarta Biosystems has received an award from CARB-X, potentially worth $9.2 million, for the development of antibiotic precision medicines.
September 16, 2019
The acquisition will enhance Lundbeck’s brain disease therapy portfolio as well as its antibody process and development capabilities.
The acquisition gives PPF a 19.2% stake in Autolus and provides a pipeline of cell therapy product candidates.
September 13, 2019
Bora Pharmaceuticals has announced it has achieved success in the latest FDA general inspection of its Zhunan facility with zero 483 observations.
ACG Group has announced the winners of its ‘Art in a Capsule’ competition, where entrants were challenged to create miniature works of art that could fit inside a capsule.
BioCity has invested in Maxwellia, a company based at Alderley Park in the United Kingdom that is driving industry movement towards self-care therapeutics.
BIA has signed a memorandum of understanding with AstraZeneca and the Wuxi International Life-science Innovation Campus (I-Campus) to boost access for UK SMEs in China.
EC has granted marketing authorization approval to Roche for Tecentriq (atezolizumab), in combination with chemotherapy, as a first-line treatment for patients with extensive-stage small cell lung cancer.
The ABPI and BMA have issued responses to the publication of a government report into the scale and distribution of prescribed medicines in England.